Skip Navigation
Search Menu
Find an Expert


Georges Jabboure Netto, M.D.

Photo of Dr. Georges Jabboure Netto, M.D.

Professor of Pathology


Languages: English, Arabic, French

Expertise: Pathology

Research Interests: Prognostic and targeted therapies; Secondary tumors of the GU system; Prostatic intraepithelial neoplasia; Testicular cancer; Bladder cancer; Kidney cancer; Prostate cancer; Molecular biomarkers; Urologic malignancies more

Request an Appointment

I live in Maryland

Request an appointment through MyChart!

I live outside of Maryland

Request Appointment

I live outside of the United States

Request Appointment


The Johns Hopkins Hospital
Appointment Phone: 410-955-3580

600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map

Johns Hopkins Outpatient Center
Appointment Phone: 410-955-3580

601 N. Caroline St.
Baltimore, MD 21287 map

Johns Hopkins Bayview Medical Center
Appointment Phone: 410-955-3580

4940 Eastern Avenue
Baltimore, MD 21224 map


Dr. Georges J. Netto is a pathologist of Sibley Memorial Hospital and a professor of pathology, oncology and urology at the Johns Hopkins School of Medicine, as well as a consultant in the nationally recognized Johns Hopkins urologic pathology laboratory. Dr. Netto is also the director of surgical pathology molecular diagnostics at Johns Hopkins. He is board certified in anatomic and clinical pathology, and molecular genetic pathology. Dr. Netto practices out of Sibley’s Prostate Cancer Multidisciplinary Clinic in Washington, D.C. and the Johns Hopkins Hospital, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins Bayview Medical Center in Baltimore, MD. 

Dr. Netto has an expertise in genitourinary pathology, molecular pathology and molecular diagnostics.  

Dr. Netto earned his medical degree from Damascus University in Syria. He completed a residency in anatomic and clinical pathology at Baylor University Medical Center, followed by a fellowship in oncology and urologic pathology at the Barnes-Jewish Hospital and a fellowship at the Memorial Sloan-Kettering Cancer Center. 

Dr. Netto is a member of the American College of Medical Genetics, the American Society of Clinical Pathology, the Association of Molecular Pathology, the College of American Pathology, the International Academy of Pathology and the International Academy of Pathology - Arab Division. 

Dr. Netto has contributed to over 200 peer-reviewed articles, co-authored books in urologic pathology, co-edited a textbook in genomic applications in pathology and lectured worldwide on the diagnostic and molecular aspects of urologic pathology. He has conducted research focusing on the evaluation of molecular biomarkers that can serve as potential therapeutic targets in the management of urologic malignancies, as well as molecular diagnostic applications with potential roles in screening and early detection of urologic malignancies. He has also conducted prostate cancer studies with grants from the Prostate Cancer Foundation, the Patrick C. Walsh Foundation and an National Institutes of Health (NIH)/National Cancer Institute (NCI)-sponsored Johns Hopkins Prostate SPORE grant. Dr. Netto’s research on urothelial carcinoma was supported by the 2008 FAMRI Clinical Innovator Award, the philanthropic Bladder Fund and NIH/NCI sponsored grants. Dr. Netto has served as a reviewer for The Journal of Urology, Archives of Pathology & Laboratory Medicine and various other publications. Currently, Dr. Netto is the associate editor for the basic and translational section of the gold journal “Urology” and the associate editor of Urology Case Reports. more


  • Professor of Pathology
  • Professor of Oncology

Departments / Divisions



  • MD, Damascus University (1985)


  • Baylor University Medical Center / Anatomic and Clinical Pathology (1992)


  • Barnes-Jewish Hospital / Anatomic Pathology (1993)
  • Memorial Sloan-Kettering Cancer Center (1994)

Board Certifications

  • American Board of Pathology / Anatomic & Clinical Pathology (1992)
  • American Board of Pathology / Molecular Genetic Pathology (2005)

Research & Publications

Research Summary

Dr. Netto’s current research focuses on the evaluation of molecular biomarkers that can serve as potential prognosticators or therapeutic targets in the management of urologic malignancies.

These studies are facilitated by the construction of tissue microarrays coupled with image-analysis technology to be used for immunohistochemistry and FISH analysis of prostatic, bladder, renal and testicular cancers. He also focuses on the molecular diagnostic applications with potential roles in screening and early detection of urologic malignancies.

Ongoing prostate cancer studies are evaluating the role of TMPRSS2-ERG translocation, proliferation markers and mTOR pathway members in predicting prostate cancer progression. The studies are funded by grants from the Prostate Cancer Foundation and the Patrick C. Walsh Foundation, as well as with an NIH/NCI-sponsored Johns Hopkins Prostate SPORE grant.

Studies on urothelial carcinoma involve evaluation of biomarkers in a newly constructed tissue array from a well characterized cohort of cystectomy patients treated at the Brady Urological Institute. Markers being studied include cell-cycle control elements, EGFR expression and mutation analysis, PIK3CA mutation analysis, DNA damage-response elements and mTOR pathway members.

These studies are supported by a 2008 FAMRI Clinical Innovator Award, philanthropic Bladder Fund and NIH/NCI sponsored grants including a PO1 program award.

Additional urologic oncology studies are examining biomarkers of targeted therapies in renal-cell carcinoma, including TOPOIIa, HIF1a/VEGF and mTOR pathway.

Selected Publications

  1. Klock C, Gomes R, João M, Netto G. Prostate Melanosis Associated With Acinar Adenocarcinoma. Int J Surg Pathol. 2010 Oct;18(5):379-80. doi: 10.1177/1066896908329591.
  2. Albadine R, Wang W, Brownlee NA, Toubaji A, Billis A, Epstein JI, Argani P, Garvin AJ, Couzi R, Schaeffer E, Pavlovich CP, Netto GJ. "Topoisomerase IIA Status in Renal Medullary Carcinoma: Immunoexpression and Gene Copy Alterations of a Potential Target of Therapy. J Urol. 2009 Aug;182(2):735-40. doi: 10.1016/j.juro.2009.03.078.
  3. K Fujita, CP Pavlovich, G Netto, Y Konishi, WB Isaacs, S Ali, A De Marzo and A Meeker. "Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology." Hum Pathol. 2009 Jul;40(7):924-33. doi: 10.1016/j.humpath.2009.01.004. Epub 2009 Apr 14.
  4. Lotan TL, Toubaji A, Albadine R, Latour M, Herawi M, Meeker AK, De Marzo AM, Platz EA, Epstein JI, Netto GJ. "TMPRSS2-ERG Gene Fusions are Infrequent in Prostatic Ductal Adenocarcinomas." Modern Pathol. 2009 Mar;22(3):359-65. doi: 10.1038/modpathol.2008.236.
  5. Cheung WL, Albadine R, Chan T, Sharma R, Netto GJ. "Phosphorylated H2AX in Non-Invasive Low Grade Urothelial Carcinoma of Urinary Bladder: Correlation with Tumor Recurrence." J Urol. 2009 Mar;181(3):1387-92. doi: 10.1016/j.juro.2008.10.146. Epub 2009 Jan 20.

Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.Proc Natl Acad Sci U S A. 2013; PMCID: PMC3625331

Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg MP, Bivalacqua T, Allaf ME, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ. TERT Promoter Mutations Occur Early in Urothelial Neoplasia and are Biomarkers of Early Disease and Disease Recurrence in Urine. Cancer Res. 2013; PMCID: PMC3966102

Zheng X, Zhuge J, Bezerra SM, Faraj SF, Munari E, Fallon JT, Yang XJ, Argani P, Netto GJ, Zhong M. High Frequency of TERT mutations in Small Cell Carcinoma of Bladder. J Hematol Oncol. 2014 Jul 20;7:47.PMCID: PMC4223615.

Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, Partin AW, De Marzo AM, Platz EA, Netto GJ. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol 2011; Nov;24(11):1511-20. PMCID: PMC3360950

Albadine R, Latour M, Toubaji A, Haffner M, Isaacs WB, A Platz E, Meeker AK, Demarzo AM, Epstein JI, Netto GJ. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol 2009; 22(11):1415-22 PMCID: PMC3354529

Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM, Netto GJ. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 2011; Jul;35(7):1014-20. PMCID: PMC3505676

Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen Y-B,Neilsen ME, Gonzalgo ML, Sidransky D, Schoenberg M, Netto GJ. Expression status and prognostic significance of mTOR pathway members in urothelial carcinoma of urinary bladder following cystectomy. Cancer 2010;116(23):5517-26. PMCID:PMC3568488

Schultz L, Chaux A, Albadine R, Hicks J, Kim JJ, De Marzo AM, Allaf ME, Carducci MA, Rodriguez R, Hammers H, Argani P, Reuter VE, Netto GJ. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol 2011;35(10):1549-56. PMCID: PMC3505672

Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA, Netto GJ. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol. 2012 Nov;25(11):1543-9. PMCID: PMC4380219

Chaux A, Munari E, Cubilla AL, Hicks J, Lecksell K, Burnett AL, Netto GJ. Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases.Histopathology. 2014;64(6):863-71.PubMed PMID: 24279699.

Activities & Honors


  • American College of Medical Genetics
  • American Society of Clinical Pathology
  • Association of Molecular Pathology
  • College of American Pathology
  • International Academy of Pathology
  • International Academy of Pathology (Arab Division)
Is this you? Edit Profile